A Metabolically-Stabilized Phosphonate Analog of Lysophosphatidic Acid Attenuates Collagen-Induced Arthritis

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Nikitopoulou, Ioanna ^a   Kaffe, Eleanna ^a   Sevastou, Ioanna ^a   Sirioti, Ivi ^a   Samiotaki, Martina ^a   Madan, Damian ^b   Prestwich, Glenn D ^c   Aidinis, Vassilis ^a  

^a BIOMEDICAL SCIENCES RESEARCH CENTER ALEXANDER FLEMING   (Greece)

^b ECHELON BIOSCIENCES INC   (United States)

^c UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 BROMOHYDROXY 4 (PALMITOYLOXY)BUTYLPHOSPHONATE; AUTOTAXIN; COLLAGEN; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; PHOSPHONIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG MECHANISM; DRUG STABILITY; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; IC 50; MAXIMUM PLASMA CONCENTRATION; MOUSE; NONHUMAN; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, RHEUMATOID; COLLAGEN; ENZYME ACTIVATION; FEMALE; HYDROLYSIS; LYSOPHOSPHATIDYLCHOLINES; LYSOPHOSPHOLIPIDS; MICE; PHOSPHORIC DIESTER HYDROLASES; SUBSTRATE SPECIFICITY;

EID: 84880763396     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070941     Document Type: Article

References (84)

1. McInnes IB, Schett G, (2011) The pathogenesis of rheumatoid arthritis. N Engl J Med 365: 2205-2219.
2. Scott DL, Wolfe F, Huizinga TW, (2010) Rheumatoid arthritis. Lancet 376: 1094-1108.
3. Strand V, Kimberly R, Isaacs JD, (2007) Biologic therapies in rheumatology: lessons learned, future directions. Nat Rev Drug Discov 6: 75-92.
4. van Vollenhoven RF, (2009) Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 5: 531-541.
5. McInnes IB, Schett G, (2007) Cytokines in the pathogenesis of rheumatoid arthritis. Nat Rev Immunol 7: 429-442.
6. Muller-Ladner U, Pap T, Gay RE, Neidhart M, Gay S, (2005) Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. Nat Clin Pract Rheumatol 1: 102-110.
7. Muller-Ladner U, Ospelt C, Gay S, Distler O, Pap T, (2007) Cells of the synovium in rheumatoid arthritis. Synovial fibroblasts. Arthritis Res Ther 9: 223.
8. Bottini N, Firestein GS, (2012) Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors. Nat Rev Rheumatol 9: 24-33.
9. Boutin JA, Ferry G, (2009) Autotaxin. Cell Mol Life Sci 66: 3009-3021.
10. Sevastou I, Kaffe E, Mouratis MA, Aidinis V, (2013) Lysoglycerophospholipids in chronic inflammatory disorders: The PLA(2)/LPC and ATX/LPA axes. Biochimica et biophysica acta 1831: 42-60.
11. van Meeteren LA, Moolenaar WH, (2007) Regulation and biological activities of the autotaxin-LPA axis. Prog Lipid Res 46: 145-160.
12. Stefan C, Jansen S, Bollen M, (2005) NPP-type ectophosphodiesterases: unity in diversity. Trends Biochem Sci 30: 542-550.
13. Umezu-Goto M, Kishi Y, Taira A, Hama K, Dohmae N, et al. (2002) Autotaxin has lysophospholipase D activity leading to tumor cell growth and motility by lysophosphatidic acid production. J Cell Biol 158: 227-233.
14. Aoki J, (2004) Mechanisms of lysophosphatidic acid production. Semin Cell Dev Biol 15: 477-489.
15. Choi JW, Lee CW, Chun J, (2008) Biological roles of lysophospholipid receptors revealed by genetic null mice: an update. Biochim Biophys Acta 1781: 531-539.
16. Ishii S, Noguchi K, Yanagida K (2009) Non-Edg family lysophosphatidic acid (LPA) receptors. Prostaglandins Other Lipid Mediat.
17. Lin ME, Herr DR, Chun J, (2010) Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 91: 130-138.
18. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, et al. (1992) Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267: 2524-2529.
19. Houben AJ, Moolenaar WH, (2011) Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 30: 557-565.
20. Liu S, Murph M, Panupinthu N, Mills GB, (2009) ATX-LPA receptor axis in inflammation and cancer. Cell Cycle 8: 3695-3701.
21. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, et al. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 209: 925-933.
22. Zhao C, Fernandes MJ, Prestwich GD, Turgeon M, Di Battista J, et al. (2008) Regulation of lysophosphatidic acid receptor expression and function in human synoviocytes: implications for rheumatoid arthritis? Molecular Pharmacology 73: 587-600.
23. Albers HM, Ovaa H (2012) Chemical Evolution of Autotaxin Inhibitors. Chem Rev.
24. Tigyi G, (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161: 241-270.
25. Im DS, (2010) Pharmacological tools for lysophospholipid GPCRs: development of agonists and antagonists for LPA and S1P receptors. Acta Pharmacol Sin 31: 1213-1222.
26. Clair T, Koh E, Ptaszynska M, Bandle R, Liotta L, et al. (2005) L-histidine inhibits production of lysophosphatidic acid by the tumor-associated cytokine, autotaxin. Lipids in Health and Disease 4: 5.
27. van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, et al. (2005) Inhibition of Autotaxin by Lysophosphatidic Acid and Sphingosine 1-Phosphate. J Biol Chem 280: 21155-21161.
28. Gududuru V, Zeng K, Tsukahara R, Makarova N, Fujiwara Y, et al. (2006) Identification of Darmstoff analogs as selective agonists and antagonists of lysophosphatidic acid receptors. Bioorg Med Chem Lett 16: 451-456.
29. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, et al. (2006) Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 281: 22786-22793.
30. Jiang G, Xu Y, Fujiwara Y, Tsukahara T, Tsukahara R, et al. (2007) Alpha-substituted phosphonate analogues of lysophosphatidic acid (LPA) selectively inhibit production and action of LPA. ChemMedChem 2: 679-690.
31. Prestwich GD, Gajewiak J, Zhang H, Xu X, Yang G, et al. (2008) Phosphatase-resistant analogues of lysophosphatidic acid: Agonists promote healing, antagonists and autotaxin inhibitors treat cancer. Biochim Biophys Acta 8: 8.
32. Albers HM, Dong A, van Meeteren LA, Egan DA, Sunkara M, et al. (2010) Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci U S A 107: 7257-7262.
33. Gierse JK, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L,et al. (2010) A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation. J Pharmacol Exp Ther.
34. Zhang H, Xu X, Gajewiak J, Tsukahara R, Fujiwara Y, et al. (2009) Dual activity lysophosphatidic acid receptor pan-antagonist/autotaxin inhibitor reduces breast cancer cell migration in vitro and causes tumor regression in vivo. Cancer Res 69: 5441-5449.
35. Xu X, Prestwich GD, (2010) Inhibition of tumor growth and angiogenesis by a lysophosphatidic acid antagonist in an engineered three-dimensional lung cancer xenograft model. Cancer 116: 1739-1750.
36. Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S,et al. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatology 54: 920-930.
37. Yang G, Zhang H, Prestwich GD, (2012) Tissue-Engineered "Metastases": Treatment of Hepatic Colon Tumors with a Dual Action Autotaxin Inhibitor-Lysophosphatidic Acid Receptor Antagonist. Journal of Cancer Research Updates 1: 69-77.
38. Bai Z, Cai L, Umemoto E, Takeda A, Tohya K,et al. (2013) Constitutive Lymphocyte Transmigration across the Basal Lamina of High Endothelial Venules Is Regulated by the Autotaxin/Lysophosphatidic Acid Axis. J Immunol.
39. Fischer DJ, Nusser N, Virag T, Yokoyama K, Wang D, et al. (2001) Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Molecular Pharmacology 60: 776-784.
40. Noguchi K, Ishii S, Shimizu T, (2003) Identification of p2y9/GPR23 as a novel G protein-coupled receptor for lysophosphatidic acid, structurally distant from the Edg family. The Journal of biological chemistry 278: 25600-25606.
41. Virag T, Elrod DB, Liliom K, Sardar VM, Parrill AL, et al. (2003) Fatty alcohol phosphates are subtype-selective agonists and antagonists of lysophosphatidic acid receptors. Molecular Pharmacology 63: 1032-1042.
42. Plows D, Kontogeorgos G, Kollias G, (1999) Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 162: 1018-1023.
43. Brand DD, Latham KA, Rosloniec EF, (2007) Collagen-induced arthritis. Nat Protoc 2: 1269-1275.
44. Aidinis V, Carninci P, Armaka M, Witke W, Harokopos V, et al. (2005) Cytoskeletal rearrangements in synovial fibroblasts as a novel pathophysiological determinant of modeled rheumatoid arthritis. PLoS Genet 1: e48.
45. Folch J, Lees M, Sloane Stanley GH, (1957) A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226: 497-509.
46. Giganti A, Rodriguez M, Fould B, Moulharat N, Coge F, et al. (2008) Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem 283: 7776-7789.
47. Nakamura K, Kishimoto T, Ohkawa R, Okubo S, Tozuka M, et al. (2007) Suppression of lysophosphatidic acid and lysophosphatidylcholine formation in the plasma in vitro: proposal of a plasma sample preparation method for laboratory testing of these lipids. Anal Biochem 367: 20-27.
48. Tokumura A, Miyake M, Yoshimoto O, Shimizu M, Fukuzawa K, (1998) Metal-ion stimulation and inhibition of lysophospholipase D which generates bioactive lysophosphatidic acid in rat plasma. Lipids 33: 1009-1015.
49. Ferry G, Moulharat N, Pradere JP, Desos P, Try A,et al. (2008) S32826: a Nanomolar Inhibitor of Autotaxin. Discovery, Synthesis and Applications as a Pharmacological Tool. J Pharmacol Exp Ther.
50. Cheng HC, (2001) The power issue: determination of KB or Ki from IC50. A closer look at the Cheng-Prusoff equation, the Schild plot and related power equations. J Pharmacol Toxicol Methods 46: 61-71.
51. Taube J, McWilliam N, Luddington R, Byrne CD, Baglin T, (1999) Activated protein C resistance: effect of platelet activation, platelet-derived microparticles, and atherogenic lipoproteins. Blood 93: 3792-3797.
52. Ferguson CG, Bigman CS, Richardson RD, vanMeeteren LA, Moolenaar WH, et al. (2006) Fluorogenic Phospholipid Substrate to Detect Lysophospholipase D/Autotaxin Activity. Org Lett 8: 2023-2026.
53. Hoeglund AB, Bostic HE, Howard AL, Wanjala IW, Best MD, et al. (2010) Optimization of a pipemidic acid autotaxin inhibitor. J Med Chem 53: 1056-1066.
54. Parrill AL, Echols U, Nguyen T, Pham TC, Hoeglund A, et al. (2008) Virtual screening approaches for the identification of non-lipid autotaxin inhibitors. Bioorg Med Chem 16: 1784-1795.
55. Saunders LP, Cao W, Chang WC, Albright RA, Braddock DT, et al. (2011) Kinetic analysis of autotaxin reveals substrate-specific catalytic pathways and a mechanism for lysophosphatidic acid distribution. The Journal of biological chemistry 286: 30130-30141.
56. Moolenaar WH, Perrakis A, (2011) Insights into autotaxin: how to produce and present a lipid mediator. Nat Rev Mol Cell Biol 12: 674-679.
57. Federico L, Pamuklar Z, Smyth SS, Morris AJ, (2008) Therapeutic potential of autotaxin/lysophospholipase d inhibitors. Curr Drug Targets 9: 698-708.
58. Tokumura A, Majima E, Kariya Y, Tominaga K, Kogure K, et al. (2002) Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 277: 39436-39442.
59. van Meeteren LA, Ruurs P, Christodoulou E, Goding JW, Takakusa H, et al. (2005) Inhibition of autotaxin by lysophosphatidic acid and sphingosine 1-phosphate. J Biol Chem 280: 21155-21161.
60. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, et al. (2003) Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63: 5446-5453.
61. Croset M, Brossard N, Polette A, Lagarde M, (2000) Characterization of plasma unsaturated lysophosphatidylcholines in human and rat. Biochem J 345 Pt 1: 61-67.
62. Ojala PJ, Hirvonen TE, Hermansson M, Somerharju P, Parkkinen J, (2007) Acyl chain-dependent effect of lysophosphatidylcholine on human neutrophils. J Leukoc Biol 82: 1501-1509.
63. Weltzien HU, Arnold B, Reuther R, (1977) Quantitative studies on lysolecithin-mediated hemolysis. Use of ether-deoxy lysolecithin analogs with varying aliphatic chain-lengths. Biochimica et biophysica acta 466: 411-421.
64. Hausmann J, Kamtekar S, Christodoulou E, Day JE, Wu T, et al. (2011) Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol 18: 198-204.
65. Aoki J, Inoue A, Okudaira S, (2008) Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 1781: 513-518.
66. Fotopoulou S, Oikonomou N, Grigorieva E, Nikitopoulou I, Paparountas T, et al. (2010) ATX expression and LPA signalling are vital for the development of the nervous system. Dev Biol 339: 451-464.
67. Tokumura A, Carbone LD, Yoshioka Y, Morishige J, Kikuchi M, et al. (2009) Elevated serum levels of arachidonoyl-lysophosphatidic acid and sphingosine 1-phosphate in systemic sclerosis. Int J Med Sci 6: 168-176.
68. Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L,et al. A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther 334: 310-317.
69. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, et al. (2010) Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 9: 71.
70. Nochi H, Tomura H, Tobo M, Tanaka N, Sato K, et al. (2008) Stimulatory role of lysophosphatidic acid in cyclooxygenase-2 induction by synovial fluid of patients with rheumatoid arthritis in fibroblast-like synovial cells. J Immunol 181: 5111-5119.
71. Zhao C, Sardella A, Chun J, Poubelle PE, Fernandes MJ, et al. (2011) TNF-alpha promotes LPA1- and LPA3-mediated recruitment of leukocytes in vivo through CXCR2 ligand chemokines. J Lipid Res 52: 1307-1318.
72. Watterson KR, Lanning DA, Diegelmann RF, Spiegel S, (2007) Regulation of fibroblast functions by lysophospholipid mediators: potential roles in wound healing. Wound Repair Regen 15: 607-616.
73. Aidinis V, Plows D, Haralambous S, Armaka M, Papadopoulos P, et al. (2003) Functional analysis of an arthritogenic synovial fibroblast. Arthritis Res Ther 5: R140-157.
74. Stanczyk J, Ospelt C, Gay RE, Gay S, (2006) Synovial cell activation. Curr Opin Rheumatol 18: 262-267.
75. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, et al. (2009) Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 15: 774-780.
76. Lee DM, Kiener HP, Agarwal SK, Noss EH, Watts GF, et al. (2007) Cadherin-11 in synovial lining formation and pathology in arthritis. Science 315: 1006-1010.
77. Zhang Y, Chen YC, Krummel MF, Rosen SD, (2012) Autotaxin through Lysophosphatidic Acid Stimulates Polarization, Motility, and Transendothelial Migration of Naive T Cells. J Immunol 189: 3914-3924.
78. Ohta H, Sato K, Murata N, Damirin A, Malchinkhuu E, et al. (2003) Ki16425, a subtype-selective antagonist for EDG-family lysophosphatidic acid receptors. Mol Pharmacol 64: 994-1005.
79. Monach PA, Mathis D, Benoist C (2008) The K/BxN arthritis model. Curr Protoc Immunol Chapter 15: Unit 15 22.
80. Orosa B, Gonzalez A, Mera A, Gomez-Reino JJ, Conde C (2012) Lysophosphatidic acid receptor 1 suppression sensitizes rheumatoid fibroblast-like synoviocytes to TNF-induced apoptosis. Arthritis Rheum.
81. Jiang G, Madan D, Prestwich GD, (2011) Aromatic phosphonates inhibit the lysophospholipase D activity of autotaxin. Bioorg Med Chem Lett 21: 5098-5101.
82. Ferry G, Tellier E, Try A, Gres S, Naime I, et al. (2003) Autotaxin is released from adipocytes, catalyzes lysophosphatidic acid synthesis, and activates preadipocyte proliferation. Up-regulated expression with adipocyte differentiation and obesity. J Biol Chem 278: 18162-18169.
83. Oikonomou N, Mouratis MA, Tzouvelekis A, Kaffe E, Valavanis C, et al. (2012) Pulmonary autotaxin expression contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Cell Mol Biol 47: 566-574.
84. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bundey RA, et al. (2010) A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. Br J Pharmacol 160: 1699-1713.